Errors in Abstract, Results, Tables, and Figures

No authors listed

Published Erratum

No authors listed. JAMA Dermatol. 2024.

. 2024 May 1;160(5):582.

doi: 10.1001/jamadermatol.2024.0241.

No abstract available

Erratum for

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Paller AS, et al. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. JAMA Dermatol. 2023. PMID: 37043227 Free PMC article. Clinical Trial.

1. Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023;159(5):526-535. doi:10.1001/jamadermatol.2023.0391 - DOI - PMC - PubMed
1. Paller AS. Reanalysis of study after removal of participants in 1 trial of upadacitinib for atopic dermatitis. JAMA Dermatol. Published online March 20, 2024. doi:10.1001/jamadermatol.2024.0194 - DOI - PubMed